Using nerve ultrasound to guide treatment for CIDP
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study uses ultrasound to look at nerves in people with CIDP to help guide treatment. It aims to see if ultrasound can help doctors choose the best therapy for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of CIDP that is not the pure sensory (mainly numbness) type.
- You must be able to attend study visits for exams, nerve tests, ultrasound, and blood draws.
- You must be willing to give written consent and have health insurance.
- You may be newly diagnosed and about to start IVIg, or have had treatment that didn't work well enough.
- Your nerve condition should not be explained by another cause, like a metabolic or hereditary problem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
This study tests if ultrasound can find nerve problems in people with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), and if it helps doctors diagnose and predict outcomes early.
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
This study tests whether a drug called obinutuzumab can help people with chronic inflammatory demyelinating polyradiculoneuropathy (a condition where the immune system attacks the nerves, causing weakness and numbness). The drug aims to reduce the immune attack and improve symptoms.
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
Hear when a new CIDP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.